肥胖药物治疗的未来前景
本文系统综述2021至2026年新一代肥胖药物临床试验,指出基于肠-胰腺激素的疗法不仅减重显著,还可改善血糖、心血管事件、心衰症状、阻塞性睡眠呼吸暂停、代谢相关脂肪性肝炎、慢性肾病进展及骨关节炎疼痛,支持以并发症为中心的表型导向治疗。
要点
- GLP-1类药物的减重幅度约为10-15%,多通路靶向药物的减重效果更显著。
- 替尔泊肽、CagriSema和amycretin的减重幅度超过20%,三重激动剂retatrutide超过25%。
- 新一代肥胖药物可带来心血管、心衰、睡眠呼吸暂停、脂肪性肝炎、肾病和骨关节炎等器官特异性获益。
核心结论
- 新一代肥胖药物疗法是肥胖管理的重大进步,支持以改善肥胖相关并发症和代谢健康为优先的达标治疗策略。
- 有效实施需要个体化治疗,并关注长期安全性、可及性和公平提供。
研究设计与样本
- 通过Medline数据库系统检索2021至2026年发表的文献,使用MeSH词和关键词筛选新一代肥胖药物治疗相关文章。
- 纳入评估成人新兴肥胖药物的2期和3期临床试验,报告减重和肥胖相关并发症等结局。
主要发现
- 靶向GLP-1、GIP、胰淀素和胰高血糖素通路的肠-胰腺激素疗法通过互补机制调节食欲、能量平衡和代谢稳态。
- GLP-1类药物实现约10-15%的减重,而多通路靶向药物效果更佳。
- 替尔泊肽、CagriSema和amycretin减重超过20%,三重激动剂retatrutide减重超过25%。
- 这些药物改善血糖、支持糖尿病预防,并产生器官特异性获益,包括减少心血管事件、改善心衰症状、降低阻塞性睡眠呼吸暂停严重程度、改善代谢功能障碍相关脂肪性肝炎、延缓慢性肾病进展和减轻骨关节炎相关疼痛。
关键数值与推荐
- GLP-1类药物的减重幅度约为10-15%。
- 替尔泊肽、CagriSema和amycretin的减重幅度超过20%。
- 三重激动剂retatrutide的减重幅度超过25%。
临床怎么用
- 临床应转向以表型为导向、以并发症为中心的肥胖管理,优先改善肥胖相关并发症和代谢健康。
- 实施个体化治疗,并关注长期安全性、药物可及性和公平提供。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Obesity is a chronic relapsing disease associated with substantial morbidity, mortality, and health care costs. Contemporary obesity pharmacotherapies extend beyond weight reduction, with evidence for improvements across multiple obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care. EVIDENCE ACQUISITION: A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026. Reference lists of relevant reviews were screened to identify additional eligible studies. Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included. EVIDENCE SYNTHESIS: Entero-pancreatic hormone-based therapies targeting glucagon-Like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, amylin, and glucagon pathways demonstrate substantial efficacy beyond weight reduction. These hormones act through complementary mechanisms regulating appetite, energy balance, and metabolic homeostasis. GLP-1 based agents achieve approximately 10-15% weight loss, whereas agents targeting multiple pathways demonstrate greater efficacy. Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20% and the triple agonist retatrutide produced reductions exceeding 25%. Beyond weight loss, these agents improve glycemia, support diabetes prevention, and produce organ-specific benefits, including reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, improvement of metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and reduced osteoarthritis-related pain. CONCLUSION: Next-generation obesity pharmacotherapies represent a major advance in obesity management and support a treat-to-target approach prioritizing improvement in obesity-related complications and metabolic health. Effective implementation will require individualized therapy and attention to long-term safety, access, and equitable delivery of care.
引用
- Bassatne A, Rizo I. Medical treatments for obesity: what does the future have in store? J Clin Endocrinol Metab. 2026. PMID: 42444567. doi:10.1210/clinem/dgag274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。